Procollagen iii n-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis

Journal of Infectious Diseases

Volumn 208, Issue 10, 2013, Pages 1571-1578

  Seddon, Jo ^a,b   Kasprowicz, Victoria ^c,d   Walker, Naomi F ^a,b,e   Yuen, Ho Ming ^f   Sunpath, Henry ^c,g   Tezera, Liku ^f,h   Meintjes, Graeme ^b,e   Wilkinson, Robert J ^a,b,i   Bishai, William R ^c   Friedland, Jon S ^a,b   Elkington, Paul T ^a,f,h,j  

^a Infectious Diseases and Immunity   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g MCCORD HOSPITAL   (South Africa)

^h UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^j UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

Extracellular matrix; Immunopathology; Lung; Matrix metalloproteinase; Mycobacteria

Indexed keywords

DESMOSINE; ELASTIN; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ARTICLE; BIODEGRADATION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MATRIX METALLOPROTEINASE 8 BLOOD LEVEL; PLASMA; PREDICTION; PRIORITY JOURNAL; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SECRETION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; SPUTUM EXAMINATION;

EXTRACELLULAR MATRIX; IMMUNOPATHOLOGY; LUNG; MATRIX METALLOPROTEINASE; MYCOBACTERIA;

BIOLOGICAL MARKERS; COINFECTION; DESMOSINE; EXTRACELLULAR MATRIX; HIV SEROPOSITIVITY; MATRIX METALLOPROTEINASES; PEPTIDE FRAGMENTS; PROCOLLAGEN; REPRODUCIBILITY OF RESULTS; ROC CURVE; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84888607870     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit343     Document Type: Article

References (40)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010; 328:856-61.
2. Fennelly KP, Jones-Lopez EC, Ayakaka I, et al. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2012; 186:450-7.
3. Elkington PT, D'Armiento JM, Friedland JS. Tuberculosis immunopathology: The neglected role of extracellular matrix destruction. Sci Transl Med 2011; 3:71ps6.
4. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003; 362:887-99.
5. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11:343-54.
6. Wang X, Jiang J, Cao Z, Yang B, Zhang J, Cheng X. Diagnostic performance of multiplex cytokine and chemokine assay for tuberculosis. Tuberculosis (Edinb) 2012; 92:513-20.
7. Chegou NN, Essone PN, Loxton AG, et al. Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS ONE 2012; 7: e38501.
8. Djoba Siawaya JF, Chegou NN, van den Heuvel MM, et al. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine 2009; 47:132-6.
9. McNerney R, Daley P. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol 2011; 9: 204-13.
10. Brust B, Lecoufle M, Tuaillon E, et al. Mycobacterium tuberculosis lipolytic enzymes as potential biomarkers for the diagnosis of active tuberculosis. PLoS ONE 2011; 6:e25078.
11. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875-80.
12. Dorman SE, Chihota VN, Lewis JJ, et al. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS ONE 2012; 7:e43307.
13. Elkington P, Shiomi T, Breen R, et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 2011; 121:1827-33.
14. Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 2007; 87:69-98.
15. Lim M, Martinez T, Jablons D, et al. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett 1998; 441:88-92.
16. Kwan CK, Ernst JD. HIV and tuberculosis: A deadly human syndemic. Clin Microbiol Rev 2011; 24:351-76.
17. Walker NF, Clark SO, Oni T, et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am J Respir Crit Care Med 2012; 185:989-97.
18. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 121:1645-54.
19. Ma S, Lieberman S, Turino GM, Lin YY. The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. Proc Natl Acad Sci U S A 2003; 100:12941-3.
20. Shapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J Clin Invest 1991; 87:1828-34.
21. Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: A promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184:637-41.
22. Stone PJ, Gottlieb DJ, O'Connor GT, et al. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 952-9.
23. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998; 158:1432-41.
24. Lammi L, Kinnula V, Lahde S, et al. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Eur Respir J 1997; 10: 2725-30.
25. Lammi L, Ryhanen L, Lakari E, et al. Type III and type I procollagen markers in fibrosing alveolitis. Am J Respir Crit Care Med 1999; 159:818-23.
26. Mannello F. Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008; 28:611-4.
27. Leroy V, Monier F, Bottari S, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99:271-9.
28. Haukipuro K, Risteli L, Kairaluoma MI, Risteli J. Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings. Surgery 1990; 107:381-8.
29. Riou C, Perez Peixoto B, Roberts L, et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS ONE 2012; 7:e36886.
30. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-46.
31. Sandhu G, Battaglia F, Ely BK, et al. Discriminating active from latent tuberculosis in patients presenting to community clinics. PLoS ONE 2012; 7:e38080.
32. Maertzdorf J, Ota M, Repsilber D, et al. Functional correlations of pathogenesis- driven gene expression signatures in tuberculosis. PLoS ONE 2011; 6:e26938.
33. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
34. Salgame P. MMPs in tuberculosis: granuloma creators and tissue destroyers. J Clin Invest 2011; 121:1686-8.
35. Nandi B, Behar SM. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med 2011; 208:2251-62.
36. Foronjy RF, Nkyimbeng T, Wallace AM, et al. The transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008; 294:1149-57.
37. Yoder MA, Lamichhane G, Bishai WR. Cavitary pulmonary tuberculosis: The Holey Grail of disease transmission. Current Sci 2004; 86:74-81.
38. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 2009; 30:769-82., ix.
39. Sander CR, Pathan AA, Beveridge NE, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis- infected individuals. Am J Respir Crit Care Med 2009; 179: 724-33.
40. Uhlin M, Andersson J, Zumla A, Maeurer M. Adjunct immunotherapies for tuberculosis. J Infect Dis 2012; 205 (Suppl 2):S325-34.